Christos Mantzoros
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1275512808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $206,189 of the $242,959 with a category attached, or 84.9%. 16 manufacturers reported payments, led by Coherus Oncology, Inc. at 24.9% of the total. 2025 is the largest year on record at $123,837, more than ten times the $2,782 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $1327.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coherus Oncology, Inc.$60K
- Boehringer Ingelheim$40K
- Regeneron$39K
- Amgen$30K
- Esperion Therapeutics, Inc.$19K
- Novo Nordisk$18K
- plus $36K from 10 others
Across 106 payments — averaging $6978.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coherus Oncology, Inc.$220K
- Merck$201K
- Abbott$135K
- Boehringer Ingelheim$89K
- Novo Nordisk$83K
- Boehringer Ingelheim International GmbH$12K
What the payments were for
- Consulting fees$206,18985%
- Speaking & faculty fees$17,2627%
- Travel & lodging$15,0626%
- Food & beverage$4,4482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coherus Oncology, Inc. | 13 | $60,450 |
| Boehringer Ingelheim | 44 | $39,971 |
| Regeneron | 53 | $38,924 |
| Amgen | 20 | $30,457 |
| Esperion Therapeutics, Inc. | 6 | $19,095 |
| Novo Nordisk | 12 | $18,270 |
| Madrigal Pharmaceuticals | 18 | $13,813 |
| Olympus Corporation | 3 | $6,035 |
| Azurity Pharmaceuticals, Inc. | 2 | $5,700 |
| Intercept Pharmaceuticals, Inc. | 1 | $4,200 |
| Abbott | 3 | $3,282 |
| Corcept Therapeutics | 3 | $2,447 |
| AstraZeneca | 2 | $193 |
| Merck | 1 | $66 |
| Amarin Pharma, Inc. | 1 | $35 |
| Boehringer Ingelheim International GmbH | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$12,339
- REZDIFFRA$11,376
- NEXLIZET$4,300
- NEXLETOL$4,300
- Architect$3,049
- Repatha$2,616
- Korlym$2,363
- RESMETIROM$1,950
- Parsabiv$1,430
- FREESTYLE LIBRE 3$233
How this compares
$242,959 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
- Andrea CovielloBoston$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.